Evaluating subcutaneous versus intravenous immunotherapies: considerations for clinical practice
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/aetw2665 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Tina Tran und 5 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibitors have significantly advanced cancer treatment. Traditionally administered intravenously, recent approvals of subcutaneous (SQ) formulations of agents such as nivolumab and atezolizumab have introduced alternative administration methods. Although preliminary literature suggests comparable efficacy and potential benefits of SQ delivery, objective evaluation of SQ versus intravenous (IV) approaches across diverse clinical settings remains necessary. IV administration, while resource-intensive due to longer infusion times and infusion center utilization, is well-established in oncology practice. Conversely, SQ administration, marketed for shorter administration durations and potential convenience, introduces new logistical considerations including injection volume limitations, administration site restrictions, and specific monitoring and observation requirements post-injection. Despite claims of reduced chair time, realworld efficiency gains remain inadequately quantified, especially in patients already utilizing ports for multi-drug regimens. Additionally, comprehensive cost-effectiveness analyses are limited, warranting a detailed assessment of the true economic impact of SQ adoption compared to IV.
Zitieren
APA
Tran, T., Truong, J., Anonuevo, M., Montes, J., Haaf, C., & Naffakh, N. (2026). Evaluating subcutaneous versus intravenous immunotherapies: considerations for clinical practice. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/aetw2665
Vancouver
Tran T, Truong J, Anonuevo M, Montes J, Haaf C, Naffakh N. Evaluating subcutaneous versus intravenous immunotherapies: considerations for clinical practice. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/aetw2665
BibTeX
@article{Tran2026,
author = {Tran, Tina and Truong, Jennifer and Anonuevo, Michael and Montes, Jacki and Haaf, Christina and Naffakh, Noor},
title = {Evaluating subcutaneous versus intravenous immunotherapies: considerations for clinical practice},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/aetw2665}
}
EUVIMED